# A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

> **NCT06581055** · — · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** Luspatercept
- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT06581055
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11-30
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581055, "A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06581055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*